TransMedics Group/$TMDX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About TransMedics Group
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
- Ticker
- $TMDX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 898
- Headquarters
- Andover, United States
- Website
- www.transmedics.com
TMDX Metrics
BasicAdvanced
$2.3B
16.44
$4.01
1.88
-
Price and volume
Market cap
$2.3B
Beta
1.88
52-week high
$156.00
52-week low
$60.11
Average daily volume
810K
Financial strength
Current ratio
6.625
Quick ratio
5.869
Long term debt to equity
1.629
Total debt to equity
1.675
Interest coverage (TTM)
3.84%
Profitability
EBITDA (TTM)
115.629
Gross margin (TTM)
58.69%
Net profit margin (TTM)
22.69%
Operating margin (TTM)
12.21%
Effective tax rate (TTM)
-109.08%
Revenue per employee (TTM)
$740,000
Management effectiveness
Return on assets (TTM)
4.33%
Return on equity (TTM)
36.28%
Valuation
Price to earnings (TTM)
16.438
Price to revenue (TTM)
3.389
Price to book
4.4
Price to tangible book (TTM)
4.5
Price to free cash flow (TTM)
28.658
Free cash flow yield (TTM)
3.49%
Free cash flow per share (TTM)
2.303
Growth
Revenue change (TTM)
25.82%
Earnings per share change (TTM)
98.94%
3-year revenue growth (CAGR)
64.17%
3-year earnings per share growth (CAGR)
92.86%
What the Analysts think about TMDX
Analyst ratings (Buy, Hold, Sell) for TransMedics Group stock.
Analyst projections of the future price of TransMedics Group stock.
Bulls say / Bears say
Second-quarter revenue rose 21% to $189.9 million, driven by higher OCS use and logistics, and TransMedics raised the low end of its 2026 revenue guidance. That points to continued demand growth across its core platform. (SEC)
The logistics network is showing signs of better utilisation: the company covered 86% of air missions with its own fleet in Q2, up from 82% in Q1, while service gross margin improved sequentially. Greater fleet use could help strengthen the economics of its integrated model. (The Motley Fool)
TransMedics is pursuing growth outside its established US business: Italy has secured national reimbursement for machine perfusion and services, and the company is bidding for regional logistics contracts there. If it wins contracts, its existing logistics model could reach more European transplant centres. (The Motley Fool)
Profitability is under pressure even as sales grow: Q2 net income fell to $14.7 million from $34.9 million a year earlier, and management expects a lower 2026 adjusted operating margin of 12.5%–14%. Heavy investment and the cost mix are limiting near-term operating leverage. (PR Newswire, The Motley Fool)
Revenue remains concentrated in liver: Q2 liver revenue was about $148 million, compared with $33 million from heart and $2 million from lung. That leaves the growth case reliant on a single organ category while heart and lung expansion still depends on clinical programmes. (The Motley Fool)
Legal scrutiny is an unresolved overhang: a shareholder securities lawsuit remains ongoing, and a law firm announced an investigation into the company’s officers and directors. These developments create potential distraction and liability, though the allegations have not been established as fact. (TMCnet)
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2026.
TMDX Financial Performance
Revenues and expenses
TMDX Earnings Performance
Company profitability
Upcoming events
No upcoming events
TMDX News
AllArticlesVideos
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
Business Wire2 months ago
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
Newsfile Corp2 months ago
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion
MarketBeat2 months ago
Funds containing TMDX
AllUSDEURGBP
Fund name | Fund size | $TMDX weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.13% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.13% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.08% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.